^
BIOMARKER:

PALB2 mutation

i
Other names: PALB2, Partner And Localizer Of BRCA2, FANCN, Truncated Partner And Localizer Of BRCA2, Fanconi Anemia, Complementation Group N, Mutant Partner And Localizer Of BRCA2, PNCA3
Entrez ID:
Related biomarkers:
PALB2 mutation
Pancreatic Adenocarcinoma
cisplatin + gemcitabine
Sensitive: A2 - Guideline
PALB2 mutation
Prostate Cancer
olaparib
Sensitive: A2 - Guideline
PALB2 mutation
HER2 Negative Breast Cancer
talazoparib
Sensitive: A2 - Guideline
PALB2 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive: A2 - Guideline
PALB2 mutation
Ovarian Cancer
olaparib
Sensitive: B - Late Trials
PALB2 mutation
Pancreatic Cancer
ABT-888
Sensitive: C2 – Inclusion Criteria
PALB2 mutation
Pancreatic Cancer
rucaparib
Sensitive: C2 – Inclusion Criteria
PALB2 mutation
Breast Cancer
olaparib
Sensitive: C2 – Inclusion Criteria
PALB2 mutation
Urothelial Cancer
olaparib
Sensitive: C2 – Inclusion Criteria
PALB2 mutation
HER2 Negative Breast Cancer
durvalumab
Sensitive: C2 – Inclusion Criteria
PALB2 mutation
Triple Negative Breast Cancer
everolimus
Sensitive: C3 – Early Trials
PALB2 mutation
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive: C3 – Early Trials
PALB2 mutation
Hormone Receptor Positive Breast Cancer
lenvatinib
Resistant: C3 – Early Trials
PALB2 mutation
Pancreatic Cancer
oxaliplatin
Sensitive: C3 – Early Trials
PALB2 mutation
Prostate Cancer
PARP inhibitor
Sensitive: C3 – Early Trials
PALB2 mutation
Pancreatic Ductal Adenocarcinoma
cisplatin + gemcitabine
Sensitive: C3 – Early Trials
PALB2 mutation
Endometrial Cancer
rucaparib + E 3810
Sensitive: C4 – Case Studies
PALB2 mutation
Triple Negative Breast Cancer
carboplatin + docetaxel
Sensitive: D – Preclinical